Yale-METRO Metropolitan Emergency Trial netwoRK to advance patient Outcomes

耶鲁-大都会推进患者预后紧急试验网络(Yale-Metro)是以耶鲁-纽黑文卫生系统(YNHHS)为中心，以及5个领先的综合卫生系统(1)哈特福德卫生保健系统、(2)罗德岛/布朗大学卫生系统、(3)西奈山卫生系统、(4)纽约长老会/威尔康奈尔医学和(5)蒙特菲奥里卫生系统。耶鲁-纽黑文医院是美国第七大医院，与YNHHS和Spokes及其各自的网络合作，这些地理位置相近的机构覆盖了人口稠密的集水区，覆盖康涅狄格州、罗德岛州、纽约州东南部、马萨诸塞州南部和纽约市4个行政区的800多万人，有1,739,027人次的急诊科就诊，为数量众多且多样化的成人和儿科急病患者提供服务。首席研究员Gail D‘OnoFrio博士(急诊医学)和Kevin Sheth博士(神经病学)带来了一套互补的领导技能、高水平的临床试验经验和出色的组织框架。每一位都证明了领导和进行多中心试验的专业知识，以及即使在新冠肺炎大流行期间，也有高质量的急诊室和院前招募以及研究保留的可靠记录。他们与发言机构和调查人员合作并积极参与多中心试验。这些互动包括利用NIH网络目前的成功贡献，如NeuroNEXT和Stroke Net。他们可以接触到一支令人印象深刻的多专业教员队伍，创造一个高度协作的环境，专注于与演示和感兴趣的诊断相关的紧急护理，包括神经、心血管、呼吸、血液学和创伤。最后，他们创建了便利注册的机制，这些机制已经到位，每周7天，每天24小时。这一建议得到了以下方面的加强：(1)拥有国家认可的研究人员和具有实施多中心试验经验的MPI的有才华的研究人员队伍；(2)庞大而多样的患者群体(3)信息学家和分析团队，为快速采用SPOKS、招募、数据收集、监测和质量带来创新的技术战略和流程；(4)指导初级调查人员的良好记录；(5)在制定未来SIREN研究提案方面的专业知识。耶鲁-麦德龙提供进行高质量研究的所有组件，并提供独特的机会，将创新技术进步用于疾病检测、患者登记、数据收集和高质量保证程序。因此，耶鲁-麦德龙提供了独特的机会来加强SIREN网络，设计、测试和发现改善患者预后的干预和治疗方法。

The Yale-Metropolitan Emergency Trial network to advance patient Outcomes (Yale-METRO) is anchored by Yale New Haven Health System (YNHHS) as the Hub and 5 leading partner integrated health systems (1) Hartford Healthcare, (2) Rhode Island/Brown University Health System, (3) Mount Sinai Health System, (4) New York Presbyterian/Weill Cornell Medicine, and (5) Montefiore Health System. Yale-New Haven Hospital is the 7th largest hospital in the U.S. and in collaboration with YNHHS and the Spokes with their respective networks these geographically proximate institutions, cover a densely populated catchment area including more than 8 million people throughout Connecticut, Rhode Island, Southeast NY, Southern MA, and 4 boroughs of New York City, with 1,739,027 Emergency Department visits offering access to a large and diverse population of acutely ill adult and pediatric patients. Principal Investigators Dr. Gail D'Onofrio (Emergency Medicine) and Dr. Kevin Sheth (Neurology) bring a complementary set of leadership skills, high-level clinical trial experience, and an excellent organizational framework. Each have demonstrated expertise in leading and conducting multicenter trials, and a proven track record of high-quality ED and pre-hospital recruitment, and retention in studies, even during the COVID-19 Pandemic. They have collaborated and are actively engaged in multicenter trials with the Spoke institutions and investigators. These interactions include leveraging successful contributions currently in place for NIH networks such as NeuroNEXT and Stroke Net. They have access to a cadre of impressive multispecialty faculty, creating a highly collaborative environment focused on the emergency care related to presentations and diagnoses of interest including, neurological, cardiovascular, respiratory, hematology and trauma. Finally, they have created mechanisms to facilitate enrollment 24 hours, 7 days a week that are already in place. The proposal is strengthened by a: (1) Pool of talented investigators with nationally recognized researchers and MPIs with experience implementing multicenter trials (2) Large diverse patient population (3) Informaticist and analytic team bringing innovative technological strategies and processes for rapid uptake of Spokes, recruitment, data collection, monitoring and quality; (4) Robust track record of mentoring junior investigators and (5) Expertise in developing future proposals for SIREN research. Yale-METRO offers all the components for conducting high-quality research and unique opportunities to use innovative technology advances for disease detection, patient enrollment, data collection and high-quality assurances procedures. Thus, Yale-METRO offers unique opportunities to strengthen the SIREN Network, designing, testing, and discovering interventions and therapies improving patient outcomes.